warnings
WARNING Administration of folic acid alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin B12 is deficient.
Folic Acid
openFDA label record#
Cross-check layer: This is openFDA JSON-derived label data. Use the corresponding DailyMed SPL as the canonical label.
Verified complete openFDA source JSON
- Brand name
- Folic Acid
- Generic name
- FOLIC ACID
- Manufacturer
- Preferred Pharmaceuticals Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- b4c3a754-64cd-499a-a32f-a6e935c41355
- SPL ID
- a45f83d1-e6fa-4301-8868-e858d177f882
- Version
- 4
- Effective date
- 2026-04-22
- Source export date
- 2026-08-01
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-08-01/8ac060fefb6f4d67c41cc2c9e4330286ca93c48094c18386c11bf706a1d8bd34/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- bdd1454d0606b622b70458a306b8a10d8a8787db06fd9f46e69c7f7a4524b630
- Import run
- 20260801T225920Z
- Imported at
- 2026-08-01 23:28:36
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 211064 | derived:openfda.application_number |
| application number | ANDA211064 | openfda.application_number | |
| brand name | Folic Acid | openfda.brand_name | |
| generic name | FOLIC ACID | openfda.generic_name | |
| manufacturer name | Preferred Pharmaceuticals Inc. | openfda.manufacturer_name | |
| ndc | package | 68788-8557-3 | openfda.package_ndc |
| ndc | package | 68788-8557-6 | openfda.package_ndc |
| ndc | package | 68788-8557-9 | openfda.package_ndc |
| ndc | package | 68788-8557-1 | openfda.package_ndc |
| ndc | product | 68788-8557 | openfda.product_ndc |
| ndc11 | package | 68788855701 | derived:openfda.package_ndc |
| ndc11 | package | 68788855703 | derived:openfda.package_ndc |
| ndc11 | package | 68788855706 | derived:openfda.package_ndc |
| ndc11 | package | 68788855709 | derived:openfda.package_ndc |
| rxcui | 310410 | openfda.rxcui | |
| spl id | a45f83d1-e6fa-4301-8868-e858d177f882 | id | |
| spl set id | b4c3a754-64cd-499a-a32f-a6e935c41355 | set_id | |
| unii | 935E97BOY8 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folic acid. Folic acid is relatively nontoxic in man. Rare instances of allergic responses to folic acid preparations have been reported and have included erythema, skin rash, itching, general malaise, and respiratory difficulty due to bronchospasm. One patient experienced symptoms suggesting anaphylaxis following injection of the drug. Gastrointestinal side effects, including anorexia, nausea, abdominal distention, flatulence, and a bitter or bad taste, have been reported in patients receiving 15 mg folic acid daily for 1 month. Other side effects reported in patients receiving 15 mg daily include altered sleep patterns, difficulty in concentrating, irritability, overactivity, excitement, mental depression, confusion, and impaired judgment. Decreased vitamin B12 serum levels may occur in patients receiving prolonged folic acid therapy. In an uncontrolled study, orally administered folic acid was reported to increase the incidence of seizures in some epileptic patients receiving phenobarbital, primidone, or diphenylhydantoin. Another investigator reported decreased diphenylhydantoin serum levels in folate-deficient patients receiving diphenylhydantoin who were treated with 5 mg or 15 mg of folic acid daily.